05.12.2019
Looking forward to CDNF results (in Finnish)
This page provides a list of some of the company’s key events in the near future. An Investor Relations calendar can be found here.
Upcoming events
Date
Event
06.02.2020
Swiss Nordic BIO 2020, Zurich, Switzerland
02.03.2020
Herantis newsletter for January-February
18.03.2020
Herantis presenting at ABGSC Investor Days at Haymarket
18.03.2020
Company presentation for Osakesäästäjät in Helsinki
04.05.2020
Herantis newsletter for March-April
26.05.2020
Herantis at ABGSC Life Science Summit
Latest releases
- Press Releases
- Earnings Releases
- First North
- Insider trading
- All
- 2020
- 2019
- 2018
- 2017
- 2016
- 2015
- 2014
30.12.2019
FN
19.12.2019
FN
16.12.2019
FN
10.12.2019
FN
02.12.2019
FN
Public materials related to our company and products will be presented on this page. Presentations in Finnish language can be found here. Please note that these presentations are provided for historical use only. Herantis will not keep these presentations up-to-date after their actual presenting date.
18.09.2019
28.03.2019
Links to public video presentations are provided on this page. Video presentation in Finnish language can be found here.
PLEASE NOTE: the presentations are for historical use only. The presentations are not kept up-to-date after their actual presenting date.
19.10.2019
19.10.2019
World Bioethics Day is a good day to learn about bioethics
Did you know that Bioethics is a very broad and challenging branch of science with potentially significant impact on our future?
30.09.2019
30.09.2019
How to invest smartly in biotech?
The big difference in biotech investments compared to more established businesses is that you need to assess a possible future success rather than consider existing cash flow and profit.
06.08.2019
06.08.2019
Artificially intelligent drug development
Artificial intelligence (AI) will shape our world in the coming years. People already speculate how AI can superhumanly solve any human problem. What will its role be in healthcare?
24.06.2019
24.06.2019
The price of life (and drugs)
Developing of novel drugs is always a high-risk endeavor and success should result in a financial reward. However, what is an acceptable cost for the treatment of severe rare disorders?
26.04.2019
26.04.2019
How big is big: The economic burden of disease
The global direct healthcare costs are approaching $10 trillion. What does that signify? The CEO gives a concrete example to elucidate the potential significance of our work.
24.01.2019
24.01.2019
Big Pharma and risk acceptance for true innovation
The development of new drugs is always risky. The more innovative an approach is the higher are the risks. For a real breakthrough in an unmet clinical need, high risk acceptance is needed.
03.10.2018
03.10.2018
A different view to Parkinson’s disease
Seppo Nieminen, a Parkinson's patient active in the regional Parkinson's group of Keski-Uusimaa in Finland, gives his thoughts on the current publishing practice on news in Parkinson's.
31.08.2018
21.12.2017
06.10.2017